- MorphoSys AG (NASDAQ:MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions.
- This write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals.
- MorphoSys decided to focus its research activities on the most advanced programs and centralize all laboratory activities at its German research hub in Planegg, Germany.
- Read Next: MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial.
- All US-based activities relating to discovery biology and drug discovery departments were discontinued.
- Early pipeline projects cannot be realized anymore, and the expected cash flows from these projects will not materialize accordingly.
- Price Action: MOR shares are down 0.93% at $6.42 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks